Cabaletta Bio, Inc. (CABA) Stock Price & How to Invest
Short answer
You can invest in Cabaletta Bio (CABA) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Cabaletta is a clinical-stage biotech building CD19-directed CAR-T cell therapies that aim to reset the immune system in autoimmune diseases, led by rese-cel (also called CABA-201). It is pre-revenue and burns cash, so the thesis rests entirely on clinical trial readouts, and the biggest risk is that an early-stage program disappoints, gets delayed, or runs out of funding before reaching the market. This is a highly speculative, binary-outcome stock.
CABA stock price
As of 2026-06-26, Cabaletta Bio, Inc. (CABA) last closed at $3.04, up 93.6% over the past year. Over the past 52 weeks it has traded between $1.33 and $4.15.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Cabaletta Bio, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Cabaletta Bio, Inc. (CABA) do?
Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune disease. Its CABA (Cabaletta Approach to B cell Ablation) platform pursues the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach, which uses CD19-directed CAR-T cells to deplete the B cells that drive autoimmune conditions, with the goal of a temporary but complete "immune system reset" rather than chronic suppression. The lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-CAR T cell therapy.
Rese-cel is being studied in the RESET (REstoring SElf-Tolerance) Phase 1/2 clinical program across multiple indications, including systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta has built a footprint of active US clinical sites with planned expansion, and has worked with the FDA on potential registrational trial designs. The company is pre-revenue, funds itself through equity raises, and has reported early clinical responses in some treated patients while emphasizing that the data remain early.
What's driving Cabaletta Bio, Inc. (CABA)?
Platform aimed at a large autoimmune market
Cabaletta is applying CD19 CAR-T, a modality already validated in blood cancers, to autoimmune diseases that today are managed with chronic immunosuppression. If the "immune reset" thesis holds across several indications, the addressable population is broad. Whether that translates into approved products depends on data that does not yet exist at registrational scale.
Multi-indication RESET program
Rather than betting on a single disease, the RESET Phase 1/2 program spans lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. This diversification means more shots on goal, but also more trials to fund and execute, and early responses in a handful of patients are not the same as controlled, durable efficacy.
Early clinical signals reported
The company has described responses or emerging responses in some patients treated with its CD19 CAR-T approach, and has engaged the FDA on potential registrational paths. These are encouraging directional signals for a clinical-stage biotech, but interpretation is limited by small numbers, short follow-up, and the absence of large randomized data.
Capital-dependent and dilution-prone
As a pre-revenue developer, Cabaletta funds operations through equity offerings, including a sizeable 2026 raise that extended its runway. Continued progress almost certainly requires further financing, which can dilute existing holders. Access to capital on acceptable terms is itself part of the investment outcome, not just the science.
What are the risks to Cabaletta Bio, Inc. (CABA)?
CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. The company has reported a going-concern consideration and relies on repeated equity raises that dilute shareholders. It also competes in a crowded autoimmune cell-therapy field where rivals such as Kyverna are further along toward a first approval, which could affect positioning even if rese-cel succeeds. A single negative data point or financing setback can move the stock sharply.
How is Cabaletta Bio, Inc. (CABA) valued? (approximate, June 27, 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cabaletta Bio, Inc.'s investor relations page or your broker.
- Share price: ~$3.04
- Market capitalization: ~$496 million
- Cash, equivalents and short-term investments: ~$116.6 million (as of March 31, 2026, before the May 2026 raise)
- 2026 financing: ~$150 million registered direct offering closed May 2026 (~$141 million net proceeds)
- Q1 2026 net loss: ~$43.5 million
- Accumulated deficit: ~$560.5 million
- Stated cash runway: Into mid-2027 after the May 2026 financing
Cabaletta is pre-profit and pre-revenue, so traditional metrics like price-to-earnings do not apply. Its value reflects the market's probability-weighted view of clinical success rather than current cash flow. Management has noted going-concern considerations, meaning the company expects to need additional capital to fund its longer-term plans.
Who competes with Cabaletta Bio, Inc. (CABA)?
Autoimmune CAR-T developers
Other companies developing engineered cell therapies for autoimmune disease, including Kyverna Therapeutics (widely viewed as furthest along, advancing miv-cel toward a potential first US filing) and Cartesian Therapeutics. These are Cabaletta's most direct comparables, and relative trial timing and data can shape how the market values each.
Large-cap and partnered cell-therapy programs
Bigger players and partnerships are pushing CD19-directed or related cell therapies into autoimmune indications, including Bristol Myers Squibb, AstraZeneca with Gracell, and Autolus Therapeutics. Their scale, manufacturing capacity, and capital can be a competitive challenge for a small clinical-stage company.
Next-generation and in vivo approaches
Newer modalities aim to deliver CD19-directed therapy without the complex manufacturing of autologous CAR-T, including in vivo approaches from companies such as Aera. If these prove safer or simpler at scale, they could pressure the economics of traditional engineered-cell therapies across the field.
Established autoimmune drug makers
Even if cell therapy works, it competes with entrenched biologics and immunosuppressants from large pharmaceutical companies that already treat lupus, myositis, and related diseases. Adoption depends on cell therapy showing meaningfully better or more durable outcomes than these existing standards of care.
How to invest in Cabaletta Bio, Inc. (CABA)
There are three common ways to get CABA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CABA sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where CABA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Cabaletta Bio, Inc. (CABA)
If you believe that CD19-directed CAR-T therapy can durably reset the immune system in autoimmune diseases like lupus, myositis, and systemic sclerosis, and that Cabaletta's rese-cel program can convert early signals into registrational data, then CABA is one way to express that view. It is a clinical-stage, pre-revenue company whose value is tied to trial outcomes, regulatory decisions, and continued access to capital rather than current earnings. The stock can move sharply on single data points, and the company itself has flagged going-concern considerations, so position sizing and time horizon matter as much as the science. None of this is a suggestion to buy or sell it.
More on Cabaletta Bio, Inc. (CABA)
Whether CABA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CABA a buy?, and where the stock could go from here in the CABA stock forecast.
For income investors, whether CABA pays a dividend and how the payout looks is covered in does CABA pay a dividend?
Build a basket around CABA with Walnut
Use Cabaletta Bio, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CABA a good stock to buy right now?
+
That depends on your risk tolerance, and this is not advice. The bull view is that CD19 CAR-T could reset the immune system across several large autoimmune markets, and rese-cel has shown early signals. The bear view is that CABA is pre-revenue, burns cash, faces going-concern considerations and dilution, and trails rivals like Kyverna toward a first approval. It is a binary, speculative stock.
What does Cabaletta Bio do?
+
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its CABA platform uses CD19-directed CAR-T cells to deplete the B cells that drive conditions such as lupus, myositis, and systemic sclerosis, aiming for a temporary but complete immune reset. Its lead candidate, rese-cel, is in the RESET Phase 1/2 program. It does not yet sell any approved products.
Is CABA profitable?
+
No. Cabaletta is a pre-revenue, clinical-stage biotech that spends heavily on research and development and reports consistent net losses, including a net loss of roughly $43.5 million in the first quarter of 2026. It had an accumulated deficit of around $560.5 million and has flagged going-concern considerations. Profitability would require an approved, commercialized product, which the company does not yet have.
Does CABA pay a dividend?
+
No. Cabaletta Bio does not pay a dividend. Like most clinical-stage biotechnology companies, it reinvests all of its capital into research, clinical trials, and operations rather than returning cash to shareholders. Pre-revenue developers that are still funding trials through equity raises generally do not pay dividends, and there is no indication that Cabaletta plans to.
What is rese-cel and the CABA platform?
+
Rese-cel (resecabtagene autoleucel, formerly CABA-201) is Cabaletta's lead candidate, a fully human CD19-directed CAR-T cell therapy. The CABA platform, short for Cabaletta Approach to B cell Ablation, engineers a patient's T cells to deplete the B cells that drive autoimmune disease. The goal is a temporary but complete immune system reset rather than the chronic suppression used by many existing treatments.
How can I buy Cabaletta Bio (CABA) stock?
+
CABA trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage account, the same way you would buy any listed stock. Some biotech or small-cap ETFs may also hold it as part of a basket. With Walnut you can hold CABA as one position inside a thematic basket alongside other names that fit your investing thesis.
Why is CABA stock so volatile?
+
CABA is a small, clinical-stage biotech with no product revenue, so its price is driven largely by expectations around clinical trial data, regulatory updates, and financing rather than earnings. Single readouts can move the stock sharply in either direction. Equity raises can dilute holders, and competitive news from rivals can also swing sentiment. This binary, news-driven profile makes it inherently volatile.
Who competes with Cabaletta Bio in autoimmune cell therapy?
+
Cabaletta competes with other autoimmune CAR-T developers such as Kyverna Therapeutics, often seen as furthest along, and Cartesian Therapeutics, plus larger or partnered efforts from Bristol Myers Squibb, AstraZeneca with Gracell, and Autolus. Newer in vivo approaches from companies like Aera, and established biologics from large pharmaceutical firms, are also part of the competitive picture.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Cabaletta Bio, Inc.'s investor relations page or your broker before making investment decisions.